Minireviews
Copyright ©The Author(s) 2023.
World J Gastrointest Surg. Apr 27, 2023; 15(4): 566-577
Published online Apr 27, 2023. doi: 10.4240/wjgs.v15.i4.566
Table 1 World Health Organization classification 2019 and grading criteria for neuroendocrine neoplasms of the gastrointestinal tract
Terminology
Differentiation
Grade
Ki-67 proliferative index (%)
Mitotic index (per 10 high-power fields)
NET, G1Well-differentiatedLow< 3< 2
NET, G2Well-differentiatedIntermediate3-202-20
NET, G3Well-differentiatedHigh> 20> 20
NEC, SCNECPoorly differentiatedHigh> 20> 20
NEC, LCNECPoorly differentiatedHigh> 20> 20
Mixed neuroendocrine-non-neuroendocrine neoplasmWell or poorly differentiatedVariableVariableVariable
Table 2 The American Joint Committee on Cancer 8th edition staging of small intestinal neuroendocrine tumors
Tumor
Description
TXThe primary tumor cannot be evaluated
T0No evidence of primary tumor
T1Tumor ≤ 1 cm and only involves the lamina propria or submucosa
T2Tumor > 1 cm or invades muscularis propria
T3Tumor invades through muscularis propria intoSub-serosal tissues without serosal invasion
T4Tumor invades serosa or other organs
Lymph nodes
NXLymph nodes cannot be assessed
N0No regional lymph node metastasis
N1Lymph node metastasis < 12 nodes
N2Lymph node metastasis ≥ 12 nodes or mesenteric masses > 2 cm
Metastases
M0No distant metastasis
M1Distant metastasis
M1aMetastasis limited to the liver
M1bMetastases in at least one extrahepatic site
M1cBoth hepatic and extrahepatic metastases
Stage
Stage IT1, N0, M0
Stage IIT2 or T3, N0, M0
Stage IIIT4, N0, M0; any T, N1 or N2, M0
Stage IVAny T, any N, M1